SLC5A2 and hydrops fetalis: Although the mechanisms responsible for the benefits of SGLT2 inhibition have only partly been elucidated and are still a matter of research, the results of many pivotal studies have inevitably affected cardiology practice and have been recognized in the most recent international guideline releases, with special focus on HF management [11].